Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide

D. Bengtsson; H. D. Schrøder; K. Berinder; D. Maiter; C. Hoybye; O. Ragnarsson; U. Feldt-Rasmussen; Rasmussen Krogh Rasmussen; A. van der Lely; M. Petersson; G. Johannsson; M. Andersen; P. Burman

doi:10.1007/s12020-018-1751-9

Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide

D. Bengtsson, H. D. Schrøder, K. Berinder, D. Maiter, C. Hoybye, O. Ragnarsson, U. Feldt-Rasmussen, Rasmussen Krogh Rasmussen, A. van der Lely, M. Petersson, G. Johannsson, M. Andersen, P. Burman^*

^*Corresponding author for this work

Department of Clinical Medicine

12 Citations (Scopus)

Original language	English
Journal	Endocrine
Volume	62
Issue number	3
Pages (from-to)	737-739
Number of pages	3
ISSN	1355-008X
DOIs	https://doi.org/10.1007/s12020-018-1751-9
Publication status	Published - 2018

Access to Document

10.1007/s12020-018-1751-9

Cite this

Bengtsson, D., Schrøder, H. D., Berinder, K., Maiter, D., Hoybye, C., Ragnarsson, O., Feldt-Rasmussen, U., Krogh Rasmussen, R., van der Lely, A., Petersson, M., Johannsson, G., Andersen, M., & Burman, P. (2018). Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide. Endocrine, 62(3), 737-739. https://doi.org/10.1007/s12020-018-1751-9

Bengtsson, D, Schrøder, HD, Berinder, K, Maiter, D, Hoybye, C, Ragnarsson, O, Feldt-Rasmussen, U, Krogh Rasmussen, R, van der Lely, A, Petersson, M, Johannsson, G, Andersen, M & Burman, P 2018, 'Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide', Endocrine, vol. 62, no. 3, pp. 737-739. https://doi.org/10.1007/s12020-018-1751-9

@article{46585e23da7e4d8d95124a45c80e5e08,

title = "Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide",

author = "D. Bengtsson and Schr{\o}der, {H. D.} and K. Berinder and D. Maiter and C. Hoybye and O. Ragnarsson and U. Feldt-Rasmussen and {Krogh Rasmussen}, Rasmussen and {van der Lely}, A. and M. Petersson and G. Johannsson and M. Andersen and P. Burman",

year = "2018",

doi = "10.1007/s12020-018-1751-9",

language = "English",

volume = "62",

pages = "737--739",

journal = "Endocrine",

issn = "1355-008X",

publisher = "Humana Press",

number = "3",

}

TY - JOUR

T1 - Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide

AU - Bengtsson, D.

AU - Schrøder, H. D.

AU - Berinder, K.

AU - Maiter, D.

AU - Hoybye, C.

AU - Ragnarsson, O.

AU - Feldt-Rasmussen, U.

AU - Krogh Rasmussen, Rasmussen

AU - van der Lely, A.

AU - Petersson, M.

AU - Johannsson, G.

AU - Andersen, M.

AU - Burman, P.

PY - 2018

Y1 - 2018

U2 - 10.1007/s12020-018-1751-9

DO - 10.1007/s12020-018-1751-9

M3 - Letter

C2 - 30246233

AN - SCOPUS:85053657322

SN - 1355-008X

VL - 62

SP - 737

EP - 739

JO - Endocrine

JF - Endocrine

IS - 3

ER -